Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Last Hour:
Last 24 Hours:

Hutchison China MediTech kicks off first human trial for potential new cancer drug

Tuesday, February 14, 2017 2:37
% of readers think this story is Fact. Add your two cents.

Hutchison China MediTech Limited (LON:HCM, NASDAQ:HCM) has launched a phase I clinical trial in Australia of a drug that takes a completely new approach to tackling cancer.

HMPL-453 targets fibroblast growth factor receptors. These are central to several biological processes including the formation of blood vessels that supply tumours (a process called  angiogenesis) as well as tissue growth and repair.

It is also thought the new drug, which is a small molecule, chemical entity rather than a harder-to-develop biologic, could prevent drug resistance.

It is a “sub-family” of the new breed of tyrosine kinases, which potentially provide an ‘on-off switch’ for cancer.

Chi-Med will look at the safety and how well tolerated the drug is while escalating the dosage.

HMPL-453 is being administered to cancer patients where treatment options have run out, so researchers will look for signs of efficacy too.

In pre-clinical studies, it was more potent and selective in the pathways targeted than other drugs in its class. It also had a favourable safety profile.

Story by ProactiveInvestors


We encourage you to Share our Reports, Analyses, Breaking News and Videos. Simply Click your Favorite Social Media Button and Share.

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Top Global

Top Alternative



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.